keyword
MENU ▼
Read by QxMD icon Read
search

Pancreatic neuroendocrin neoplasm

keyword
https://www.readbyqxmd.com/read/29331723/progesterone-arrested-cell-cycle-progression-through-progesterone-receptor-isoform-a-in-pancreatic-neuroendocrine-neoplasm
#1
Samaneh Yazdani, Atsuko Kasajima, Yoshiaki Onodera, Keely May McNamara, Kazue Ise, Yasuhiro Nakamura, Tomoyoshi Tachibana, Fuyuhiko Motoi, Michiaki Unno, Hironobu Sasano
In pancreatic neuroendocrine neoplasms (Pan-NEN) progesterone signaling has been shown to have both inhibitory and stimulatory effects on cell proliferation. The ability of progesterone to inhibit tumor proliferation is of particular interest and is suggested to be mediated through the less abundantly expressed progesterone receptor (PR) isoform A (PRA). To date the mechanistic processes underlying this inhibition of proliferation remain unclear. To examine the mechanism of PRA actions, the human Pan-NEN cell line QGP-1, that endogenously expresses PR isoform B (PRB) without PRA, was transfected with PRA...
January 10, 2018: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29329160/predictive-effect-of-the-total-number-of-examined-lymph-nodes-on-n-staging-and-survival-in-pancreatic-neuroendocrine-neoplasms
#2
Xianbin Zhang, Lili Lu, Peng Liu, Fei Cao, Yushan Wei, Li Ma, Peng Gong
OBJECTIVES: We aim to examine the predictive effect of the total number of examined lymph nodes on N stage and survival in pancreatic neuroendocrine neoplasms (pNENs) and to determine the optimal threshold. METHODS: A pNENs data set from 2004 to 2013 was extracted from the Surveillance, Epidemiology, and End Result database. Multivariate logistic regression and Cox proportional hazards model were used to identify predictive factors associated with N stage and survival, respectively...
January 12, 2018: Pancreas
https://www.readbyqxmd.com/read/29321190/genomic-landscape-of-pancreatic-neuroendocrine-tumours-the-international-cancer-genome-consortium
#3
Andrea Mafficini, Aldo Scarpa
Neuroendocrine tumours (NETs) may arise throughout the body and are a highly heterogeneous, relatively rare class of neoplasms difficult to study also for the lack of disease models. Despite this, knowledge on their molecular alterations has expanded in the latest years, also building from genetic syndromes causing their onset. Pancreatic NETs (PanNETs) have been among the most studied, and research so far has outlined a series of recurring features, as inactivation of MEN1, VHL, TSC1/2 genes, and hyperactivation of the PI3K/mTOR pathway...
January 10, 2018: Journal of Endocrinology
https://www.readbyqxmd.com/read/29309705/common-genetic-variants-associated-with-pancreatic-adenocarcinoma-may-also-modify-risk-of-pancreatic-neuroendocrine-neoplasms
#4
Ofure Obazee, Gabriele Capurso, Francesca Tavano, Livia Archibugi, Antonio De Bonis, William Greenhalf, Tim Key, Claudio Pasquali, Anna Caterina Milanetto, Thilo Hackert, Paola Fogar, Valbona Liço, Christos Dervenis, Rita T Lawlor, Luca Landoni, Maria Gazouli, Carlo Federico Zambon, Niccola Funel, Oliver Strobel, Krzysztof Jamroziak, Cinzia Cantù, Ewa Malecka-Panas, Stefano Landi, John P Neoptolemos, Daniela Basso, Renata Talar-Wojnarowska, Maria Rinzivillo, Angelo Andriulli, Federico Canzian, Daniele Campa
Pancreatic neuroendocrine neoplasms (pNEN) account for less than 5% of all pancreatic neoplasms and genetic association studies on susceptibility to the disease are limited. We sought to identify possible overlap of genetic susceptibility loci between pancreatic ductal adenocarcinoma (PDAC) and pNEN; therefore, PDAC susceptibility variants (n=23) from Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 3,277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the odds associated with pNEN risk, disease onset and tumor characteristics...
December 22, 2017: Carcinogenesis
https://www.readbyqxmd.com/read/29307199/pathologic-classification-of-pancreatic-cancers-current-concepts-and-challenges
#5
Mohamed E Mostafa, Ipek Erbarut-Seven, Burcin Pehlivanoglu, Volkan Adsay
As the most common and most important cancer of the pancreas, with rapid mortality and now also as the third leading cause of cancer-related deaths in the United States, pancreatic ductal adenocarcinoma (PDAC) has become synonymous with "pancreas cancer". PDAC is also the prototype of the "pancreatobiliary-type" adenocarcinomas, along the biliary tract, ampullary and gallbladder cancers with the similar morphology and behavior. Recent molecular profiling studies have identified distinct subsets of PDAC, potentially with different behaviors and targetability...
December 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29301491/pancreatic-panniculitis-the-bright-side-of-the-moon-in-solid-cancer-patients
#6
Elena Guanziroli, Antonella Colombo, Antonella Coggi, Raffaele Gianotti, Angelo Valerio Marzano
BACKGROUND: Pancreatic panniculitis is a rare complication of pancreas disorders occurring in 0.3-3% of patients, most often accompanied by the pancreatic acinar carcinoma. It presents multiple, painful, deep, ill-defined, red-brown, migratory nodules and plaques of hard elastic consistency; often ulcerated and typically located on the lower proximal and distal extremities. The pathogenesis is not fully understood, but it is thought to result from lipolysis and fat necrosis with secondary tissue inflammation induced by pancreatic enzymes...
January 4, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29290942/identification-of-novel-serum-autoantibodies-against-eid3-in-non-functional-pancreatic-neuroendocrine-tumors
#7
Koji Hontani, Takahiro Tsuchikawa, Takaki Hiwasa, Toru Nakamura, Takashi Ueno, Toshihiro Kushibiki, Mizuna Takahashi, Kazuho Inoko, Hironobu Takano, Satoshi Takeuchi, Hirotoshi Dosaka-Akita, Masaki Kuwatani, Naoya Sakamoto, Yutaka Hatanaka, Tomoko Mitsuhashi, Hideaki Shimada, Toshiaki Shichinohe, Satoshi Hirano
Pancreatic neuroendocrine tumors (pNETs) are relatively rare heterogenous tumors, comprising only 1-2% of all pancreatic neoplasms. The majority of pNETs are non-functional tumors (NF-pNETs) that do not produce hormones, and as such, do not cause any hormone-related symptoms. As a result, these tumors are often diagnosed at an advanced stage because patients do not present with specific symptoms. Although tumor markers are used to help diagnosis and predict some types of cancers, chromogranin A, a widely used tumor marker of pNETs, has significant limitations...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29284590/peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#8
Stefano Partelli, Emilio Bertani, Mirco Bartolomei, Carolina Perali, Francesca Muffatti, Chiara Maria Grana, Marco Schiavo Lena, Claudio Doglioni, Stefano Crippa, Nicola Fazio, Giuseppe Zamboni, Massimo Falconi
BACKGROUND: Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use of peptide receptor radionuclide therapy as a neoadjuvant agent for resectable or potentially resectable pancreatic neuroendocrine neoplasms. METHODS: The postoperative outcomes of 23 patients with resectable or potentially resectable pancreatic neuroendocrine neoplasms at high risk of recurrence who underwent neoadjuvant peptide receptor radionuclide therapy (peptide receptor radionuclide therapy group) were compared with 23 patients who underwent upfront surgical operation (upfront surgery group)...
December 25, 2017: Surgery
https://www.readbyqxmd.com/read/29281757/short-term-outcomes-and-risk-factors-for-pancreatic-fistula-after-pancreatic-enucleation-a-single-center-experience-of-142-patients
#9
Xing Wang, Chun-Lu Tan, Hao Zhang, Yong-Hua Chen, Min Yang, Neng-Wen Ke, Xu-Bao Liu
BACKGROUND: Enucleation is increasingly used for benign or low-grade pancreatic neoplasms. Enucleation preserves the pancreatic parenchyma as well as decreases the risk of long-term endocrine and exocrine dysfunction, but may be associated with a higher rate of postoperative pancreatic fistula (POPF). The aim of this study was to assess short-term outcomes, in particular, POPF. METHODS: Data were collected retrospectively from all 142 patients who underwent pancreatic enucleation between 2009 and 2014 in our institution were analyzed...
December 27, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29241991/pancreatic-cyst-fluid-glucose-rapid-inexpensive-and-accurate-diagnosis-of-mucinous-pancreatic-cysts
#10
Rosalie A Carr, Michele T Yip-Schneider, Rachel E Simpson, Scott Dolejs, Justine G Schneider, Huangbing Wu, Eugene P Ceppa, Walter Park, C Max Schmidt
BACKGROUND: The most widely accepted biochemical test for preoperative differentiation of mucinous from benign, nonmucinous pancreatic cysts is cyst fluid carcinoembryonic antigen. However, the diagnostic accuracy of carcinoembryonic antigen ranges from 70% to 86%. Based on previous work, we hypothesize that pancreatic cyst fluid glucose may be an attractive alternative to carcinoembryonic antigen. METHODS: Pancreatic cyst fluid was collected during endoscopic or operative intervention...
December 11, 2017: Surgery
https://www.readbyqxmd.com/read/29239038/gastroenteropancreatic-neuroendocrine-neoplasms-selected-pathology-review-and-molecular-updates
#11
REVIEW
Siaw M Chai, Ian S Brown, M Priyanthi Kumarasinghe
Gastroenteropancreatic (GEP) neuroendocrine neoplasms can be broadly separated into well- and poorly differentiated categories. Tumours within each category have similarities in morphology and immunophenotype, but vary in grade, behaviour, molecular signature and responses to therapy. The aetiology of these differences is multifactorial. Site of origin, mucosal milieu and hereditary influences are some of the currently known factors. Given these differences, staging and grading systems continue to evolve, and the most recent World Health Organization classification of pancreatic neuroendocrine neoplasms reflects this by introducing a grade 3 neuroendocrine tumour category for morphologically well-differentiated tumours with an elevated Ki-67 proliferation index and/or mitotic count...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29239037/well-differentiated-pancreatic-neuroendocrine-tumours-pannets-and-poorly-differentiated-pancreatic-neuroendocrine-carcinomas-pannecs-concepts-issues-and-a-practical-diagnostic-approach-to-high-grade-g3-cases
#12
REVIEW
Aatur D Singhi, David S Klimstra
With increasing accessibility and advancements in abdominal imaging modalities, the incidence of pancreatic neuroendocrine neoplasms has increased steadily during the past few decades. By definition, neuroendocrine neoplasms of the pancreas show neuroendocrine differentiation, but they represent a broad and heterogeneous group of neoplasms with diverse clinical and pathological characteristics. The majority of pancreatic neuroendocrine neoplasms can be classified as well-differentiated pancreatic neuroendocrine tumours (PanNETs) or poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs)...
January 2018: Histopathology
https://www.readbyqxmd.com/read/29235006/intrinsic-contact-between-t-and-n-classifications-in-resected-well-moderately-differentiated-locoregional-pancreatic-neuroendocrine-neoplasms
#13
Jin-Zhi Xu, Wen-Quan Wang, Shi-Rong Zhang, Hua-Xiang Xu, Chun-Tao Wu, Zi-Hao Qi, He-Li Gao, Quan-Xing Ni, Liang Liu, Xian-Jun Yu
BACKGROUND: The role of N classification is controversial in several prognostication systems proposed for pancreatic neuroendocrine neoplasms (pNENs). The widely accepted modified European Neuroendocrine Tumor Society (mENETS) system suggests this contradiction may be related to T classification. METHODS: Data were collected retrospectively from 981 patients in the Surveillance, Epidemiology, and End Results (SEER) database (1973-2012; cohort 1) and 140 patients from the Pancreatic Cancer Institute of Fudan University (2006-2016; cohort 2)...
December 12, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29228674/the-regulatory-role-of-aberrant-phosphatase-and-tensin-homologue-and-liver-kinase-b1-on-akt-mtor-c-myc-axis-in-pancreatic-neuroendocrine-tumors
#14
Tsung-Ming Chang, Yan-Shen Shan, Pei-Yi Chu, Shih Sheng Jiang, Wen-Chun Hung, Yu-Lin Chen, Hsiu-Chi Tu, Hui-You Lin, Hui-Jen Tsai, Li-Tzong Chen
Pancreatic neuroendocrine tumor (pNET) is an uncommon type of pancreatic neoplasm. Low Phosphatase and Tensin Homologue (PTEN) expression and activation of the mechanistic target of rapamycin (mTOR) pathway have been noted in pNETs, and the former is associated with poor survival in pNET patients. Based on the results of the RADIANT-3 study, everolimus, an oral mTOR inhibitor, has been approved to treat advanced pNETs. However, the exact regulatory mechanism for the mTOR pathway in pNETs remains largely unknown...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29212159/lef1-tfe3-and-ar-are-putative-diagnostic-markers-of-solid-pseudopapillary-neoplasms
#15
Eun Kyung Kim, Mi Jang, Minhee Park, Hoguen Kim
The diagnosis of solid pseudopapillary neoplasms (SPNs) is challenging because some SPNs share many similar morphological and immunohistochemical features with other pancreatic neoplasms. In this study, we investigated potential diagnostic markers of SPN. Based on the SPN-specific upregulated genes from a previous DNA microarray and proteome study, we selected six immunohistochemical markers [beta-catenin, androgen receptor (AR), lymphoid enhancer-binding factor 1 (LEF1), transcription factor for immunoglobulin heavy-chain enhancer 3 (TFE3), fused in sarcoma (FUS), and WNT inhibitory factor 1 (WIF-1)]...
November 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/29196022/a-systematic-review-and-meta-analysis-on-the-role-of-palliative-primary-resection-for-pancreatic-neuroendocrine-neoplasm-with-liver-metastases
#16
REVIEW
Stefano Partelli, Roberto Cirocchi, Paola M V Rancoita, Francesca Muffatti, Valentina Andreasi, Stefano Crippa, Domenico Tamburrino, Massimo Falconi
BACKGROUND: Role of palliative pancreatic neuroendocrine neoplasm (PanNEN) resection (pPanNEN-R) is controversial. This study was designed as a meta-analysis of studies which allow a comparison of pPanNEN-R and non-surgical management (PanNEN-nR). METHODS: All published studies until 2017 allowing for the comparison of pPanNEN-R and PanNEN-nR were reviewed. Primary outcome was overall survival (OS). Secondary outcomes measures included postoperative morbidity, reoperation, readmission, length of hospital stay (LOS), and quality of life (QoL)...
November 29, 2017: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29189384/the-evolution-of-surgical-strategies-for-pancreatic-neuroendocrine-tumors-pan-nens-time-trend-and-outcome-analysis-from-587-consecutive-resections-at-a-high-volume-institution
#17
Luca Landoni, Giovanni Marchegiani, Tommaso Pollini, Sara Cingarlini, Mirko D'Onofrio, Paola Capelli, Riccardo De Robertis, Maria V Davì, Antonio Amodio, Harmony Impellizzeri, Anna Malpaga, Marco Miotto, Letizia Boninsegna, Lorenzo Crepaz, Chiara Nessi, Caterina C Zingaretti, Salvatore Paiella, Alessandro Esposito, Luca Casetti, Giuseppe Malleo, Massimiliano Tuveri, Giovanni Butturini, Roberto Salvia, Aldo Scarpa, Massimo Falconi, Claudio Bassi
OBJECTIVE: The objective of the present analysis is 2-fold: first, to define the evolution of time trends on the surgical approach to pancreatic neuroendocrine neoplasms (Pan-NENs); second, to perform a complete analysis of the predictors of oncologic outcome. BACKGROUND: Reflecting their rarity and heterogeneity, Pan-NENs represent a clinical dilemma. In particular, there is a scarcity of data regarding their long-term follow-up after surgical resection. METHODS: From the Institutional Pan-NEN database, 587 resected cases from 1990 to 2015 were extracted...
November 16, 2017: Annals of Surgery
https://www.readbyqxmd.com/read/29179516/lymph-node-ratio-but-not-the-total-number-of-examined-lymph-nodes-or-lymph-node-metastasis-is-a-predictor-of-overall-survival-for-pancreatic-neuroendocrine-neoplasms-after-surgical-resection
#18
Peng Liu, Xianbin Zhang, Yuru Shang, Lili Lu, Fei Cao, Min Sun, Zhaohui Tang, Brigitte Vollmar, Peng Gong
Aim: To evaluate the prognostic significance of lymph node metastasis, extent of examined lymph nodes (ELNs) and lymph node ratio (LNR) for resected pancreatic neuroendocrine neoplasms (pNENs). Materials and Methods: Surgically resected pNENs were assimilated from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier and Cox proportional hazard models were used to examine the prognostic effect of clinicopathological characteristics on overall survival; Harrell's concordance index was performed to assess the prognostic accuracy of all independent prognostic factors; and the Spearman's rank correlation was used to assess the correlation between LNR and other clinicopathological characteristics...
October 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/29177160/neuroendocrine-neoplasms-dichotomy-origin-and-classifications
#19
REVIEW
Günter Klöppel
Neuroendocrine neoplasms (NENs) are heterogeneous tumors with a common phenotype. There are two fundamentally different groups of NENs: well-differentiated, low-proliferating NENs, called neuroendocrine tumors (NETs) or carcinoids, and poorly differentiated, highly proliferating NENs, called small- or large-cell neuroendocrine carcinomas (NECs). This NEN dichotomy is probably due to an origin from different neuroendocrine progenitor cells. The current World Health Organization (WHO) classification of gastrointestinal NENs uses the Ki67 proliferation index to grade NETs as G1 or G2, and NECs as G3...
October 2017: Visceral Medicine
https://www.readbyqxmd.com/read/29169836/-classification-of-pancreatic-neuroendocrine-tumours-changes-made-in-the-2017%C3%A2-who-classification-of-tumours-of-endocrine-organs-and-perspectives-for-the-future
#20
Jean-Yves Scoazec, Anne Couvelard
The WHO classification of the tumors of endocrine organs, published in July 2017, has introduced significant changes in the classification of pancreatic neuroendocrine tumors, the previous version of which has appeared in 2010, within the WHO classification of the tumors of the digestive system. The main change is the introduction of a new category of well-differentiated neoplasms, neuroendocrine tumors G3, in addition to the previous categories of neuroendocrine tumors G1 and G2. The differential diagnosis between neuroendocrine tumors G3 (well-differentiated) and neuroendocrine carcinomas (poorly-differentiated) might be difficult; the authors of the WHO classification therefore suggest the use of a number of immunohistochemical markers to facilitate the distinction between the two entities...
November 20, 2017: Annales de Pathologie
keyword
keyword
29075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"